Fatal familial insomnia (FFI) is a rare, inherited neurodegenerative disorder caused by a mutation in the PRNP gene. Characterized by progressive insomnia, memory loss, and other neurological symptoms, FFI typically leads to death within 9 to 30 months of symptom onset. Currently, there is no cure; treatment focuses on symptom management. Research is ongoing to find effective treatments, including a clinical trial testing the antibiotic doxycycline.
New research suggests that Parkinson’s disease may begin in the digestive tract and spread to the brain, potentially fueled by a chain reaction initiated by gut microbes. The study, published in ACS Chemical Biology and ACS Chemical Neuroscience, highlights the role of E. coli bacteria and the formation of protein clumps in the gut, similar to those found in the brains of Parkinson’s patients. While this research is still in its early stages, it opens up exciting possibilities for understanding and potentially preventing this devastating neurodegenerative disease.
The global Multiple System Atrophy (MSA) market is experiencing significant growth, driven by the increasing prevalence of the disease, advancements in diagnostic techniques, and the development of novel treatment options. This report by CoherentMI delves into the market’s dynamics, providing insights into key segments, growth drivers, and prominent players shaping the future of MSA treatment.
Biohaven Ltd. (BHVN) surged on positive data from a pivotal study evaluating its drug candidate, troriluzole, for treating spinocerebellar ataxia (SCA). The study demonstrated the drug’s ability to slow disease progression, prompting Biohaven to file for FDA approval in late 2024. This breakthrough could provide much-needed hope for patients battling this debilitating condition.
The global market for Friedreich’s Ataxia drugs is projected to experience significant growth, reaching a value of US$ 3.49 billion by 2034. This growth is driven by increased investments in disease-modifying treatments and gene therapy, as well as supportive initiatives from governments and non-profit organizations. The market is expected to be dominated by North America, with a projected market share of 36.7% by 2034.
